FDA's comment docket on psychedelic provider training and credentialing (FDA-2026-N-7542) closes at 11:59 p.m. ET tonight, October 5, 2026, and it explicitly asks for "the evidence base for training and educational curricula." That evidence base does not exist. The first peer-reviewed landscape analysis of US facilitator training — Palitsky et al., PLOS ONE, 2026 — interviewed 13 of 20 contacted programs and found an unaccredited, inconsistent field. Oregon law (ORS 475A.325) forbids the state from requiring facilitators to hold any college degree; Oregon's rules require 128 instruction hours plus a 40-hour practicum, Colorado roughly 150 hours. No study anywhere shows that any hour count, curriculum, or credential makes clients safer. Meanwhile CIIS charges $8,900–$9,400 for a certificate that it states does not lead to licensure, and psilocybin remains federal Schedule I with no FDA-approved product.
The short answer
Federal regulators are finally asking who should be qualified to sit in a psilocybin dosing room, and the training industry that built itself out ahead of that question has no outcome evidence. The credentials are real. The validation is not.
Psychedelics Today posted a video titled "Evaluating the Next Generation of Psychedelic Higher Education." We could not read it. YouTube returned the title and the channel name and nothing else — no description, no transcript, no upload date — so we are treating it strictly as a topic hook and going straight to the documents underneath it. Nothing in this article is attributed to that video.
Those documents tell a sharper story than the title does. In 2026 the federal government asked, for the first time, who should be legally qualified to deliver psychedelic therapy. FDA's public comment docket on training and credentialing closes tonight — 11:59 p.m. ET, October 5, 2026. HRSA ran a parallel inquiry over the summer.
And the thing FDA explicitly asked for — "the evidence base for training and educational curricula" — does not exist. Not in Oregon, not in Colorado, not in the degree programs, not in the first peer-reviewed study of the field. Nobody has demonstrated that any training length, curriculum, or certificate makes a single client safer.
That is the honest center of this story. A twelve-month certificate costs roughly $9,400 and is being sold into an evidence vacuum.
What FDA and HRSA actually asked, and why now
FDA held a hearing on September 14, 2026 under docket FDA-2026-N-7542 and asked for comment on curricula, personnel needs by phase of care, and credentialing. HRSA asked whether screening requires a degree-holding professional at all. Comments to FDA close tonight.
FDA's hearing, "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs," ran 12:30–4:30 p.m. ET on September 14, 2026. The notice published July 14, 2026 at 91 FR 43095–43098, docket FDA-2026-N-7542, issued by FDA and HHS "in collaboration with federal partners" — the notice does not name which partners.
The questions are worth quoting, because they are an admission. FDA asked for comment on "the evidence base for training and educational curricula, and the expert body(ies)" that would develop or endorse them; on "personnel and training needs by phase of care"; and on "credentialing and licensure considerations, ranging from background education and experiential qualifications to supervision and practice hour requirements."
HRSA's Request for Information, published the same day at 91 FR 43103 and closed August 13, went further. It asked which training models work — "didactic, simulation-based, supervised practicum, apprenticeship, certification" — how supervision should differ across provider types, and whether screening should be done by degree-holding professionals or "trained non-professionals." It also asked what Federally Qualified Health Centers, Certified Community Behavioral Health Clinics, and Rural Health Clinics would need, and about AI tools for screening and workforce training.
https://www.federalregister.gov/documents/full_text/text/2026/07/14/2026-14146.txt
Both trace back to Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness," signed April 18, 2026 and published at 91 FR 21709. The EO directs FDA to issue National Priority Vouchers to psychedelics holding Breakthrough Therapy designation, directs FDA and DEA to establish Right to Try pathways, allocates $50 million through ARPA-H, and tells the Attorney General to review rescheduling for *approved* products. Notably, the EO itself says nothing about workforce or training.
The commercial clock is what makes this urgent. Compass Pathways announced six-month Phase 3 data on July 7, 2026: COMP006, randomized and double-blind, 581 dosed participants, with 39% of the 25 mg arm reaching a ≥25% MADRS reduction at week 6 and holding through week 26. Serious adverse events were 5.7% in the 25 mg arm versus 6.3% in the 1 mg arm. Evidence tier matters here: that is a sponsor press release on one trial, with a 1 mg active comparator and the functional-unblinding problem that haunts this entire drug class. The reported difference against comparator, –3.8 MADRS points, is statistically significant; whether it is clinically meaningful is contested. Compass guides to a final NDA submission in Q4 2026 and launch in the first half of 2027 — company guidance, not an FDA commitment. Nothing here is approved.
The first peer-reviewed look at the training industry
Palitsky et al. (PLOS ONE, 2026) interviewed 13 of 20 contacted US facilitator training programs and found shared structure but no accreditation, uneven credentials, and a gap between what programs say matters and what they teach. It is qualitative interview research, not an outcomes study.
Rebecca Palitsky, Candace Peacock, Jordan A. Breau, Patrick Gillis-Smith and Gabriela Sklodowska published "A landscape analysis of psychedelic facilitation training in the US" in *PLOS ONE* this year (DOI 10.1371/journal.pone.0350037).
https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0350037
Method first, because it bounds everything else: structured Zoom interviews conducted December 2024 through April 2025, with 13 of 20 contacted programs responding (68%), snowball and purposive sampling, member-checked. This is a qualitative interview study. It describes what programs say they do. It cannot tell you whether any of them produces a competent facilitator, and it does not claim to.
What it found:
- Every program organized its curriculum around "phases of psychedelic facilitation" — screening, preparation, dosing, integration — with emphasis on harm reduction, trauma-sensitive care, and ethics.
- Completion certificates were not universally offered. You can finish a program and have nothing to show.
- Every program called spiritual, existential, religious and theological content important. "The majority did not dedicate any curriculum components" to it, citing time and resources.
- Most preferred post-graduate trainees but made exceptions.
The funding deserves naming in the same breath as the findings: the study was commissioned by the Harvard Center for the Study of World Religions, three co-authors are CSWR employees, and two held CSWR contracts. Palitsky reports support from the Tiny Blue Dot Foundation, River Styx Foundation, Shefa Psychedelic Support, and the Common Era Fund. That is disclosed, not hidden, and it is also why the SERT finding — a religion center finding that programs skip religion — should be read with the authors' own framing rather than as a scandal.
What a facilitator credential legally qualifies you for
In Oregon, a high school diploma, 128 hours of approved instruction, a 40-hour practicum, and an exam. State law expressly forbids requiring a college degree, and no clinical license is needed. In an FDA trial, the bar is a licensed graduate-level clinician.
Oregon's statute is explicit. ORS 475A.325 requires a facilitator applicant to be 21 or older, hold "a high school diploma or equivalent education," complete approved training, and pass an exam. It then says the authority "may not require a psilocybin service facilitator to have a degree from a university, college, post-secondary institution, or other institution of higher education." No clinical license is required.
https://oregon.public.law/statutes/ors_475a.325
The hours live in rule. OAR 333-333-3050(1) requires at least 128 hours of instruction: 12 hours of historical, traditional and contemporary practices; 12 of cultural equity; 12 of safety, ethics and responsibilities; 12 of pharmacology, neuroscience and clinical research; 16 of core facilitation skills; 16 of preparation and orientation; 20 of administration; 12 of integration; 16 of group facilitation. OAR 333-333-3070(9) adds a minimum 40-hour practicum — at least 30 hours of direct client observation and 10 hours of consultation.
https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=7102
Colorado requires at least 150 hours across 14 topic areas, per the *PLOS ONE* analysis above. That is roughly 20% more classroom time than Oregon. It is a contrast, not a quality finding — no study compares outcomes between the two. Our side-by-side is at /vs/oregon-vs-colorado-psilocybin-therapy.
Now the contrast that shows how wide this gap is. FDA finalized "Psychedelic Drugs: Considerations for Clinical Investigations" on July 14, 2026 (availability notice at 91 FR 43101, docket FDA-2023-D-1987). On monitor qualifications we are relying on secondary sources only — our tooling could not parse the guidance PDF, so treat the following as reported rather than quoted from FDA. Regulatory Focus (Ferdous Al-Faruque, RAPS, July 13, 2026) reports the final guidance says an independently licensed healthcare provider with graduate-level professional training and clinical experience in psychotherapy should serve as lead monitor, and that FDA removed the draft's list of example professions after stakeholders asked to broaden eligibility. A Baker Donelson client alert (Lisa Gora, August 11, 2026) adds that two monitors per session are expected, with the assistant needing nursing or a bachelor's degree plus a year of clinical experience, and that a licensed on-call physician must be able to reach the site within 15 minutes if the lead monitor is not a physician.
So: graduate-licensed clinician in a trial, high school diploma in a licensed Oregon session. Same molecule.
What the education market charges for it
CIIS lists $8,900–$9,400 for a 12-month certificate that it states does not lead to licensure, plus $2,000–$2,600 more for the Oregon add-on. University programs are being seeded in part by a company developing a psilocybin drug.
The CIIS Certificate in Psychedelic-Assisted Therapies & Research runs 12 months, 140–150 instruction hours across eight weekends from October to May. Tuition is $9,400 hybrid in San Francisco or $8,900 online, plus a $150 application fee, an optional $600 Holotropic Breathwork module, and $2,000–$2,600 for the Oregon training add-on. The prerequisite is an advanced degree or a bachelor's in a clinical or related field. CIIS says the program "does not require or promote the use of illegal substances," and reports dispersing over $1.4 million in need-based scholarships since 2016.
Read the key sentence on their own page: it does not lead to licensure. Oregon graduates must complete additional requirements before they can even apply for a state facilitator license.
CIIS also runs what it calls "the first undergraduate degree of its kind in the nation," a B.S. in Psychedelic Studies — an online degree-*completion* program for transfer students, finishable in three semesters per department chair Anne Huffman. The page lists no licensure or career-outcome guarantees.
Then there is the University Psychedelic Education Program (U-PEP), founded by Sandy Samberg, which announced its inaugural cohort on June 13, 2025: 63 Faculty Fellows from 30 universities across 22 states, drawn from accredited schools of nursing, social work, medicine, psychology and public health, to fold psychedelic content into existing curricula. Named funders include the Steven & Alexandra Cohen Foundation, the Joe & Sandy Samberg Foundation, the 1440 Foundation, and the Usona Institute.
Usona is simultaneously a psilocybin drug developer. Its PSIL301 Phase 3 trial in major depressive disorder (NCT06308653, roughly 240 participants, launched March 2024) has completed enrollment and is listed as active, not recruiting, with primary completion January 5, 2026. No results have been reported. A drug sponsor helping fund university curriculum development is a structural conflict worth naming — not an accusation that anyone has done anything wrong, but the kind of thing readers should know when a university course tells them what psychedelic therapy is.
What this means if you are the client, not the student
Oregon's first full year of data looks reassuring on its face and is thin by design: aggregate, voluntary, with no validated outcome measures. Screening is self-attested, which puts the lithium and psychosis questions back on you.
Yu, Tafur, Moreno and Dahmer analyzed Oregon Health Authority's public aggregate dashboard for January 1 through December 31, 2025 in *Frontiers in Psychiatry* (2026;17:1777387): 5,935 clients across 5,375 administration sessions, including 747 group sessions. Adverse events ran 2.42 behavioral and 2.79 medical per 1,000 sessions — 13 and 15 cases — with seven severe reactions requiring hospitalization across the year. Nearly a third of clients, 32.6%, came from outside Oregon. The population skewed white (84–91.5%), female (57.4%) and 35–49; 27.2% identified as LGBTQ+. Top stated motivations were wellness (30.6%), perspective change (27.7%) and expanded consciousness (27.0%), with depression at 22.0% and PTSD at 13.1%.
https://pmc.ncbi.nlm.nih.gov/articles/PMC13224104/
The authors' own limitations are the point. The data are "aggregate, cross-sectional, and de-identified," so no individual can be tracked. There are no validated outcome measures. Between 3% and 19% of demographic data is missing depending on the quarter. Reporting is voluntary. And the authors note that facilitators may lack medical or mental health credentials, which may affect the quality of adverse-event reporting itself. This is observational surveillance, not a trial.
LoParco and colleagues press harder in *Health Behavior Research* (2026;9(1):20): OHA "does not license training programs," the facilitator exam allows unlimited attempts at a 75% passing threshold — raising "issues ensuring individuals have adequately acquired the necessary knowledge" — and client eligibility is self-reported only. Clients need only report no past-month lithium use and no lifetime psychosis diagnosis or treatment. No objective testing. Sessions cost $15 to $3,500 per person.
https://pmc.ncbi.nlm.nih.gov/articles/PMC13348737/
That self-attestation is why the lithium question is yours to take seriously. Nayak, Gukasyan, Barrett and colleagues analyzed online psychedelic experience reports in *Pharmacopsychiatry*: of 62 lithium-plus-psychedelic reports, 47% involved seizures and another 18% "bad trips," with 39% involving medical attention. None of 34 lamotrigine reports did. Tier check: these are self-reported trip reports, not a clinical study. The signal is strong enough to act on; the method is not strong enough to quantify your risk. Our breakdown is at /guides/psilocybin-and-lithium.
If you take SSRIs, MAOIs, benzodiazepines or stimulants, or have a personal or family history of psychosis or bipolar disorder, that belongs in front of a prescriber before it belongs in a screening form: /guides/psilocybin-drug-interactions. For dose questions, /dosage; for everything about the container, /guides/safe-trip.
PsyBear takeaways
A credential is not a competency finding. Ask what a facilitator is licensed to do, who trained them, and who paid for the training — then ask what the evidence says, and accept that the answer right now is almost nothing.
1. FDA asked for the evidence base and there isn't one. Docket FDA-2026-N-7542 closes at 11:59 p.m. ET tonight. No one — not Oregon, not Colorado, not the degree programs, not the *PLOS ONE* authors — has produced a study showing that 128 hours, 150 hours, or any credential improves client safety. Treat hour counts as regulatory decisions, not validated standards.
2. The *PLOS ONE* landscape analysis is interviews, not outcomes. Thirteen programs of twenty contacted, by Zoom, over five months. Useful map. Zero information about whether graduates are any good.
3. "Not accredited" and "not licensure" are the two phrases to look for. CIIS states plainly that its $8,900–$9,400 certificate does not lead to licensure. Oregon law bars the state from requiring any degree at all. Those two facts together explain most of the confusion in this market.
4. Follow the money in the curriculum. Usona Institute funds university psychedelic education and is running a Phase 3 psilocybin trial. The Harvard Center for the Study of World Religions commissioned the study that found programs underteach religion. Disclosed conflicts, worth weighing.
5. Oregon's safety numbers are better than nothing and weaker than they look. Seven hospitalizations across 5,375 sessions in 2025 is the real figure; voluntary aggregate reporting with no validated outcome measures and up to 19% missing demographics is the real caveat.
6. Screening is on you. Oregon clients self-attest to no past-month lithium and no lifetime psychosis. Nobody checks. If you are on lithium, that single fact should stop you. See /guides/psilocybin-and-lithium and /guides/safe-trip.
7. Nothing here is federally legal. Psilocybin and psilocin remain Schedule I under 21 CFR 1308.11(d) — DEA codes 7437 and 7438. Oregon and Colorado are state regulatory schemes only, and no psilocybin product has FDA approval. https://www.ecfr.gov/current/title-21/chapter-II/part-1308/section-1308.11
This is education and policy commentary, not medical or legal advice. A training certificate is not a clinical license, and a licensed facilitator is not a physician. Psilocybin can interact dangerously with lithium and with serotonergic and other psychiatric medications, and is contraindicated for people with a history of psychosis or bipolar disorder. Talk to a prescriber who knows your chart — not a training program's admissions page. Do not buy psilocybin from unlicensed sellers.
Key Takeaways
FDA's comment docket on psychedelic provider training and credentialing (FDA-2026-N-7542) closes at 11:59 p.m. ET tonight, October 5, 2026, and it explicitly asks for "the evidence base for training and educational curricula." That evidence base does not exist. The first peer-reviewed landscape analysis of US facilitator training — Palitsky et al., PLOS ONE, 2026 — interviewed 13 of 20 contacted programs and found an unaccredited, inconsistent field. Oregon law (ORS 475A.325) forbids the state from requiring facilitators to hold any college degree; Oregon's rules require 128 instruction hours plus a 40-hour practicum, Colorado roughly 150 hours. No study anywhere shows that any hour count, curriculum, or credential makes clients safer. Meanwhile CIIS charges $8,900–$9,400 for a certificate that it states does not lead to licensure, and psilocybin remains federal Schedule I with no FDA-approved product.
FAQ
- When does FDA's comment period on psychedelic provider training close?
- At 11:59 p.m. ET on October 5, 2026, under docket FDA-2026-N-7542. The notice published July 14, 2026 at 91 FR 43095–43098, following a public hearing on September 14, 2026, and it asks for comment on the evidence base for training curricula, personnel needs by phase of care, and credentialing and licensure considerations.
- Do you need a college degree to be a licensed psilocybin facilitator in Oregon?
- No. ORS 475A.325 requires an applicant to be 21 or older, hold a high school diploma or equivalent, complete approved training, and pass an exam — and it expressly states that the authority "may not require" a facilitator to hold a degree from any institution of higher education. No clinical license is required either.
- How many training hours does Oregon require, and how does Colorado compare?
- Oregon's OAR 333-333-3050(1) requires at least 128 hours of instruction across nine topic areas, plus a minimum 40-hour practicum under OAR 333-333-3070(9) — at least 30 hours of direct client observation and 10 hours of consultation. Colorado requires at least 150 hours across 14 topic areas, per the 2026 PLOS ONE landscape analysis. No study compares client outcomes between the two.
- Does a CIIS psychedelic certificate let you practice?
- Not by itself. CIIS lists the 12-month certificate at $9,400 hybrid or $8,900 online, with 140–150 instruction hours over eight weekends, and states that it does not lead to licensure — Oregon graduates must complete additional requirements before applying for a state facilitator license. The Oregon training add-on costs a further $2,000–$2,600.
- How safe was Oregon's first full year of regulated psilocybin services?
- Yu et al. (Frontiers in Psychiatry, 2026) analyzed OHA's aggregate dashboard for calendar 2025: 5,935 clients across 5,375 sessions, with 2.42 behavioral and 2.79 medical adverse events per 1,000 sessions and seven severe reactions requiring hospitalization. The authors caution that the data are aggregate and cross-sectional, use no validated outcome measures, are 3–19% incomplete on demographics, and rely on voluntary reporting.
- What happens if you mix psilocybin with lithium?
- An analysis of online experience reports by Nayak and colleagues in Pharmacopsychiatry found that of 62 lithium-plus-psychedelic reports, 47% involved seizures, 18% involved "bad trips," and 39% involved medical attention — while none of 34 lamotrigine reports did. These are self-reported anecdotes, not a clinical study, so the risk cannot be quantified, but the signal is serious. Oregon only asks clients to self-report no past-month lithium use, with no objective verification.